Clinical characteristics of 32 patients with BRAF V600E-mutated lung adenocarcinoma Source: International Congress 2015 – Advances in the therapy of lung cancer Year: 2015
LSC - 2017 - KRAS & TP53 mutations cause malignant mesothelioma Source: International Congress 2017 – Pleural disease and mesothelioma: from the bench to the bedside Year: 2017
EGFR, KRAS, HER2, BRAF and PI3KCA mutation status in metastatic cancer patients: Thoracic cytological specimens obtained in routine clinical practice Source: Annual Congress 2013 –Progress in bronchoscopy and pathology techniques for diagnosis of thoracic malignancies Year: 2013
KRAS & TP53 mutations cause malignant mesothelioma Source: ERS Lung Science Conference 2017 Year: 2017
Equal efficacy of gefitinib in chemonaive lung adenocarcinoma patients with either exon 19 deletion or L858R point mutation Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up Year: 2016
The prognostic value of KRAS mutation according to the gene's Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014
Cytological samples for the study of EGFR, KRAS and ALK mutations in non-small cell lung cancer Source: Annual Congress 2013 –Progress in bronchoscopy and pathology techniques for diagnosis of thoracic malignancies Year: 2013
Mapping of KRAS mutations during chemical carcinogenesis Source: Virtual Congress 2020 – Inflammatory pathways in chronic airway diseases Year: 2020
NRAS mutations destine tumor cells to the lungs Source: International Congress 2015 – New frontiers in biomedical research on thoracic tumours Year: 2015
Frequency and type of EGFR mutations in patients with adenocarcinoma of the lung Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer Year: 2013
Gene expression of EGFR, MINA53,MEN1 and MTOR in NSCLCs Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014
Lung adenocarcinoma with concomitant EGFR mutation and ALK rearrangement: Analysis of two cases and literature review Source: International Congress 2016 – Basic science and case reports in lung cancer Year: 2016
LATE-BREAKING ABSTRACT: Treatment efficacy of afatinib vs gefitinib in lung adenocarcinoma with EGFR gene mutation Source: International Congress 2016 – Prognostic variables in lung cancer II Year: 2016
Prognostic value of EGFR mutation in NSCLC in surgical stage Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014
Are KRAS mutations druggable? Source: New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine Year: 2019
Homozygous deletion of PTEN and poor outcomes in EGFR mutant NSCLC patients with gefitinib therapy Source: International Congress 2015 – Lung cancer therapy: clinical trials Year: 2015
Germ-line exon 21 EGFR mutations, V843I and P848L, in nonsmall cell lung cancer patients Source: Eur Respir Rev 2014; 23: 390-392 Year: 2014
A detailed immunohistochemical analysis of PI3K/AKT/MTOR pathway in lung cancer: Correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer Year: 2013
Novel two mechanisms for acquired EGFR-TKI resistance in lung cancer cells harboring EGFR activating mutation Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014
Gefitinib as first-line treatment for patients with NSCLC with activating EGFR mutationin exons 19 (Del19) or 21 (L858R) in the Czech Republic Source: International Congress 2015 – Lung cancer therapy: clinical trials Year: 2015